Huya Bioscience Enters Into U.S., European Deals That Could Help Channel Innovative Chinese Drugs Into Pipelines Of International Pharma Outfits
This article was originally published in PharmAsia News
Executive Summary
BEIJING - In transactions that could help channel innovative Chinese drugs into the pipelines of global pharmaceutical outfits, Huya Bioscience International has signed separate deals with the U.S.-headquartered Abbott Laboratories and the Belgian-based Solvay Pharmaceuticals to identify lead compounds for potential licensing agreements
You may also be interested in...
San Diego's Huya Signs Six New Deals With Chinese Scientific Partners, Looks To Fast Forward Global Drug Development
BEIJING - During a whirlwind tour of China, the leaders of the San Diego-headquartered Huya Bioscience have signed, in rapid succession, partnership pacts with prestigious scientific institutions in half a dozen cities on drug research and development
San Diego's Huya Signs Six New Deals With Chinese Scientific Partners, Looks To Fast Forward Global Drug Development
BEIJING - During a whirlwind tour of China, the leaders of the San Diego-headquartered Huya Bioscience have signed, in rapid succession, partnership pacts with prestigious scientific institutions in half a dozen cities on drug research and development
California's Huya And China Medical City Create Alliance To Develop Chinese Pharmaceutical Projects
SHANGHAI - Huya Bioscience International has entered into a strategic alliance to help accelerate the development of innovative R&D projects originating in China Medical City, in the Taizhou National Medical Hi-tech Development Zone